8-K: Enovis Reports Strong Q1 2025 Results, Updates Full-Year Outlook

Enovis Corporation announces an 8% increase in first-quarter sales and appoints a new CEO, while updating its full-year financial expectations.

Summary

• Enovis Corporation reported its financial results for the first quarter ended April 4, 2025.
• Net sales for the quarter were $559 million, an 8% increase on a reported basis and a 9% increase on a comparable basis compared to the same quarter in 2024.
• Reconstructive sales grew by 11%, while Prevention & Recovery (P&R) sales grew by 5% on a reported basis.
• The company reported a net loss from continuing operations of $56 million, or a loss of 10.0% of sales.
• Adjusted EBITDA was $99 million, or 17.7% of sales, representing a 160 basis point increase compared to the prior-year quarter.
• The company reported a net loss of $0.98 per share and adjusted net earnings per diluted share of $0.81.
• Enovis updated its full-year revenue expectations to $2.22-2.25 billion, compared to the prior expectation of $2.19-2.22 billion.
• Adjusted EBITDA is now forecasted to be $385-395 million, compared to the prior outlook of $405-415 million, including a $20 million tariff impact.
• Full-year adjusted earnings per share were updated from $3.10-$3.25 to $2.95-$3.10.
• Damien McDonald was appointed as CEO, effective May 12th, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to revenue growth and margin expansion, but tempered by a net loss and lowered profit guidance.

Positives

• First-quarter sales grew by 8% on a reported basis and 9% on a comparable basis.
• Reconstructive sales increased by 11% year-over-year.
• Adjusted EBITDA margin expanded by 160 basis points.
• Revenue expectations for 2025 were updated to $2.22-2.25 billion.

Negatives

• The company reported a net loss from continuing operations of $56 million, or a loss of 10.0% of sales.
• Adjusted EBITDA forecast was lowered to $385-395 million from $405-415 million due to tariff impacts.
• Full-year adjusted earnings per share were updated from $3.10-$3.25 to $2.95-$3.10.

Risks

• The company faces risks related to the acquisition of Lima.
• Public health emergencies and global pandemics could impact the company.
• Disruptions in the global economy caused by geopolitical tensions, including the situation in Ukraine, pose a risk.
• Macroeconomic conditions, including inflationary pressures, could affect the company's performance.
• Changes in government trade policies, including tariffs, could have a negative impact.
• Supply chain disruptions and increasing energy costs are potential challenges.
• The company's performance could be affected by other factors detailed in its SEC filings, including its most recent Annual Report on Form 10-K under the caption Risk Factors.

Future Outlook

Enovis updated its full-year revenue expectations to $2.22-2.25 billion. Adjusted EBITDA is forecasted to be $385-395 million, and full-year adjusted earnings per share are expected to be $2.95-$3.10.

Management Comments

• We delivered a strong start to 2025, with first-quarter revenues and margins exceeding expectations, said Matt Trerotola, Chief Executive Officer of Enovis.
• This performance reflects the strength of our business system and the discipline of our teams as we navigate a complex global environment.
• As we move forward, we remain focused on driving above-market growth through disciplined execution, strategic investment, and a multi-year cadence of high-impact product launches across our portfolio.

Industry Context

Enovis operates in the medical technology industry, specifically focusing on orthopedics. The company's performance is influenced by factors such as innovation in medical devices, regulatory requirements, and global economic conditions. The growth in reconstructive sales suggests a positive trend in demand for orthopedic solutions.

Comparison to Industry Standards

• Comparing Enovis's 8% revenue growth to competitors like Stryker (SYK) or Zimmer Biomet (ZBH) would provide a benchmark for performance in the orthopedic device market.
• The adjusted EBITDA margin of 17.7% can be compared to the margins of similar companies to assess Enovis's profitability.
• For example, Stryker's adjusted operating margin is typically in the range of 25%, so Enovis has room to improve.
• Similarly, the 11% growth in reconstructive sales can be compared to the growth rates of competitors in the same segment to evaluate Enovis's market share gains.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the revenue growth but negatively to the lowered profit guidance.
• Employees may be affected by the change in CEO.
• Customers may benefit from the company's focus on innovation and product launches.

Next Steps

• The company will host an investor conference call and live webcast to discuss the results.
• Enovis will continue to focus on driving above-market growth through disciplined execution, strategic investment, and product launches.

Key Dates

Keywords

Enovis, financial results, first quarter, net sales, adjusted EBITDA, revenue, earnings per share, medical technology, orthopedics, Damien McDonald